September 26, 2023

Catalyzing Change: Young Moroccan Oncologists Spearhead the Fight Against Sarcoma

Discover the latest insights into sarcoma and rare adult solid cancers from the recent ESMO Sarcoma and Rare Cancers Congress, underlining the significance of multidisciplinary approaches and research efforts. Voices from young oncologists shed light on the pressing need for qualified resources. #ESMO2023

The ASCO Post

June 19, 2023

Aromatase Inhibitors May Limit Effectiveness of Weight Loss Medications in Breast Cancer Survivors

Aromatase inhibitors may interfere with the efficacy of weight loss medications in breast cancer survivors, according to a new study presented by Fansa et al at the 2023 Endocrine Society Annual Meeti...

The ASCO Post

October 04, 2023

Using Recent Diagnostic Scans May Cut Time to Treatment for Patients Needing Urgent Palliative Radiotherapy

Using previously taken diagnostic CT scans in place of CT simulation scans to plan simple palliative radiation treatments may substantially reduce the time spent waiting for urgent treatment, improvin...

The ASCO Post

June 05, 2024

Impact of High Blood Insulin Levels on Triple-Negative Breast Cancer Survival in Black Women

High blood insulin levels may contribute to worse outcomes in Black women with triple-negative breast cancer, according to new findings presented at the Endocrine Society’s Annual Meeting & Exposi...

The ASCO Post

May 25, 2023

Elena Garralda, MD, MSc, Discusses Findings From the KRYSTAL-1 Trial

Elena Garralda, MD, MSc, Director of Early Drug Development at Vall d’Hebron University Hospital and Director of the Phase I Unit at NEXT Oncology, Barcelona, was invited to discuss the KRYSTAL-1 find...

The ASCO Post

September 09, 2024

What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D?

For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C gr...

The ASCO Post

April 10, 2023

William Hahn is a 2023 Award of Excellence Honoree by Hope Funds

William Hahn, MD, PhD, executive vice president and chief operating officer at Dana-Farber Cancer Institute, is one of three exceptional individuals honored by Hope Funds with its 2023 Award of Excellence in the areas of Basic Science and Medicine.

Dana-Farber

October 28, 2024

Scientists Develop a ‘Digital Twin’ Model to Predict Cancer Treatment Responses

A “digital twin” model constructed from the clinical and molecular profiles of patients with cancer may accurately predict how a patient is likely to respond to a specific chemotherapy.

The ASCO Post

November 17, 2023

Miami Cancer Institute to Present Advances in Breast Cancer Research at 2023 San Antonio Breast Cancer Symposium

Miami Cancer Institute, part of Baptist Health South Florida, today announced that its researchers will present several posters at this year’s San Antonio Breast Cancer Symposium (SABCS), hosted December 5-9 at the Henry B. Gonzalez Convention Center.

Baptist Health South Florida